Zacks Small-Cap Research

November 15, 2016
David Bautz, PhD
312-265-9471
dbautz@zacks.com

scr.zacks.com
10 S. Riverside Plaza, Chicago, IL 60606

Sophiris Bio, Inc.

(SPHS-NASDAQ)

SPHS: Preparing for Phase 2b Trial of PRX302 in Prostate Cancer…

Based on our probability adjusted DCF model that takes into account potential future revenues from PRX302 in both BPH and prostate cancer, SPHS is valued at $6/share. This model is highly dependent upon the clinical success of PRX302 and will be adjusted accordingly based upon future clinical results.

Current Price (11/15/16)	$2.93
Valuation	**$6.00**

INITIATION

On November 9, 2016, Sophiris Bio, Inc. announced financial results for the third quarter of 2016 and provided a business update. During the third quarter, the company raised net proceeds of $27.4 million and exited the quarter with approximately $31.1 million in cash and cash equivalents. In addition, the company repaid the outstanding principal balance of the loan with Oxford Finance, LLC with a total payment of $4.2 million.

Sophiris will be initiating a Phase 2b clinical trial of PRX302 for the treatment of localized prostate cancer that we expect to initiate in the first quarter of 2017 with topline results likely reported before the end of 2017.

SUMMARY DATA

52-Week High	**$5.95**
52-Week Low	**$0.83**
One-Year Return (%)	**25.75**
Beta	**1.89**
Average Daily Volume (sh)	**709,043**
Shares Outstanding (mil)	**29**
Market Capitalization ($mil)	**$85**
Short Interest Ratio (days)	**N/A**
Institutional Ownership (%)	**6**
Insider Ownership (%)	**6**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**N/A**
Earnings Per Share (%)	**N/A**
Dividend (%)	**N/A**
P/E using TTM EPS	**N/A**
P/E using 2016 Estimate	**N/A**
P/E using 2017 Estimate	**N/A**

Risk Level	**N/A,**
Type of Stock	**N/A**
Industry	**Med-Biomed/Gene**

ZACKS ESTIMATES

Revenue
(In millions of $)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2015	0.0 A	0.0 A	0.0 A	0.0 A	0.0 A
2016	0.0 A	0.0 A	0.0 A	0.0 E	0.0 E
2017					0.0 E
2018					0.0 E

Earnings per Share
(EPS is operating earnings before non-recurring items)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2015	-$0.26 A	-$0.22 A	-$0.22 A	-$0.14 A	-$0.84 A
2016	-$0.13 A	-$0.21 A	-$0.17 A	-$0.08 E	-$0.56 E
2017					-$0.33 E
2018					-$0.41 E

© Copyright 2016, Zacks Investment Research. All Rights Reserved.

WHAT'S NEW

Business Update

Sophiris Bio, Inc. (SPHS) is developing treatments for lower urinary tract symptoms of benign prostatic hyperplasia (BPH) and localized clinically significant low to intermediate risk prostate cancer. The company's lead candidate, PRX302 (topsalysin), is a genetically engineered recombinant protein that is activated through enzymatic cleavage by prostate specific antigen (PSA), which is produced in large quantities by the prostate gland. Once activated, topsalysin combines with other topsalysin molecules to form stable transmembrane pores and initiate cell death. The compound has been successfully tested in one Phase 3 clinical trial for BPH and a Phase 2a clinical trial for localized prostate cancer.

PRX302 (Topsalysin)

Proaerolysin is an inactive precursor protein secreted by the *Aeromonas* genus of Gram-negative, anaerobic bacteria (Buckley, 1992). Once released by the bacterium, proaerolysin binds to the surface of target cells, where it is cleaved by furin-like proteases to produce aerolysin (Abrami *et al*., 1998). Activation of aerolysin results in the formation of a heptameric oligomer that inserts into the cell membrane forming a transmembrane pore. Loss of small molecules and ions through the channels eventually leads to cell death.

The specific cleavage of proaerolysin is due to the presence of the furin cleavage sequence KVRRAR located within the protein. Furin is a ubiquitous protease that is produced by most cell types, thus native proaerolysin can be activated throughout the body. In order to target the molecule to the prostate for use as a potential therapeutic agent, the furin cleavage sequence was replaced with a prostate specific antigen (PSA)-selective cleavage sequence HSSKLQ (Denmeade *et al*., 1997). PSA is a protease produced by the prostate gland, and while it is found in the bloodstream, the vast majority of circulating PSA is bound by protease inhibitors and thus is enzymatically inactive (Christensson *et al*., 1990). Enzymatically active PSA is found almost exclusively in normal and malignant prostate tissue (Olsson *et al*., 2005). A schematic showing the mechanism of action for topsalysin (PRX302) is shown in the following figure.



***Source*: Sophiris Bio, Inc.**

Prostate Cancer

Prostate cancer is the most common non-cutaneous cancer diagnosed in men. It is typically a slow growing cancer, although it still accounts for approximately 10% of all cancer related deaths in men. Currently, most of the cases of prostate cancer are found through routine screening of prostate specific antigen (PSA) level, although some cases are also identified as an incidental pathological finding when tissue is removed during transurethral resection to manage obstructive prostatic symptoms.

The American Cancer Society estimates that approximately 180,890 men will be diagnosed with prostate cancer in 2016, while approximately 26,120 men will die from the disease (SEER database). Approximately 80% of those diagnosed will have localized disease. Half of those will have low-risk disease that is unlikely to ever spread outside of the prostate, however the other half of those with localized disease will have intermediate- or high-risk disease that is more suited to treatment.

The disease is quite rare in men less than 40 years of age, and is still uncommon in men younger than 50. Sixty percent of cases are in men aged 65 or older and the average age of diagnosis is 66. Prevalence rates are significantly higher in African-Americans than in White or Hispanic populations, although the exact reasons for this are unclear (Hoffman *et al*., 2001). In addition to age and race, other risk factors include geography, as most cases occur in North American, Northwestern Europe, Australia, and the Caribbean Islands, and genetics, as prostate cancer appears to run in some families.

PRX302 in Localized Prostate Cancer

Treating prostate cancer with PRX302 is possible due to the high levels of enzymatically active PSA that surround prostate lesions. In addition, MRI imaging can be combined with real-time 3D ultrasound in order to target the treatment specifically to a histologically proven, clinically significant lesion, thus sparing surrounding healthy prostate tissue and offering a more favorable safety profile.

Thus far PRX302 has been tested in a proof-of-concept clinical study in patients with localized low-to-intermediate risk prostate cancer (NCT02499848). It was a single center, open label, six month study in 18 men that were administered PRX302 to treat a single, histologically proven, clinically significant lesion. Patients needed to have a Gleason score of 7 and ≤ 10 mm Maximum Cancer Core Length (MCCL) or a Gleason score of 6 and > 3 mm MCCL. The primary outcome of the study was safety and tolerability over six months with secondary outcomes examining histological and MRI evidence of tumor control over six months.

The company released biopsy results from the 18 patients in June 2016. The data showed that two men experienced complete ablation of their targeted tumor with no evidence of tumor remaining at six months, seven men experienced a partial response, defined as either a reduction in the MCCL or a reduction in Gleason pattern, and nine patients had no response to treatment.

Two very important findings from the study in relation to dosing and administration of PRX302 were identified that could lead to greater efficacy in future clinical trials:

- PRX302 was administered at a dose of 5 µg/g of prostate tissue. One of the key findings from the prostate cancer trial was that dosing should be performed based on the size of the tumor, not the prostate. An analysis of treatment response based on the size of the tumor for the Phase 2a trial showed that most of the responders in the study received > 500 µg PRX302/g of tumor while for those that did not respond most received < 500 µg PRX302/g of tumor.

- The delivery of PRX302 will be optimized in future trials by attaching the injection needle to an infusion pump such that the drug can be administered slowly, thus allowing it to diffuse into the tumor cells and surrounding regions. The company reported that some of the patients in the Phase 2a study had tumors that were very dense, and when the drug was injected it was not able to properly saturate the tumor. By decreasing the rate at which the drug is injected, the company believes that PRX302 will be more likely to stay in the tumor microenvironment and fully penetrate the tumor tissue.

The fact that two patients saw a complete response in the proof-of-concept clinical trial is very encouraging, as the study was only designed to allow for a greater understanding of the optimal dose and delivery method for PRX302. Based on the data obtained thus far, we believe that PRX302 could offer men with low-to-intermediate risk prostate cancer the potential to have their lesion ablated, or at least decreased to a size that warrants active surveillance as opposed to radical treatment (e.g., radical prostatectomy).

Development Plan for PRX302 in Prostate Cancer

Sophiris will follow up on the results of the Phase 2a clinical trial of PRX302 in prostate cancer with a Phase 2b study involving approximately 40 patients with localized clinically significant low to intermediate risk prostate cancer that should begin in the first quarter of 2017. As mentioned above, the dose of PRX302 is likely to be based on the size of the tumor, and will likely be up to 1000 µg PRX302/g of tumor. Administration of the drug will be performed with an infusion pump to decrease the rate of injection and standardize the treatment delivery across clinical sites. We anticipate topline results to be released before the end of 2017. We estimate this trial will cost approximately $4 to $6 million.

Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia (BPH) is growth of the prostate gland as a result of unregulated proliferation of connective tissue, smooth muscle, and glandular epithelial cells (Auffenberg *et al*., 2009). The increase in cell growth leads to an increase in prostate volume and the formation of nodules in the periurethral zone. As the nodules increase in size, they can lead to compression of the urethra, resulting in increased resistance to urine flow from the bladder. While an increase in PSA expression is sometimes seen in those with BPH, the condition is not associated with an increased risk of cancer.

BPH can lead to various lower urinary tract symptoms (LUTS), a term used to describe a wide range of symptoms related to the bladder, prostate, and urethra. LUTS are grouped into voiding or storage symptoms, and include

- ✓ A longer than usual wait for urination to begin
- ✓ A weak urine stream
- ✓ Straining to urinate
- ✓ Involuntary interruption in urination
- ✓ Frequent urination
- ✓ An urgent feeling to urinate
- ✓ Waking at night two or more times to urinate

BPH is considered a normal part of aging in men, with an estimated 50% of men demonstrating histopathological BPH by the age of 60 and 90% of men by age 85. Up to 14 million men in the U.S. and 30 million men worldwide have symptoms of BPH (NIDDK).

Diagnosis of BPH is made based on a history of LUTS, a digital rectal exam (DRE), and the ruling out of other etiologies, since other diseases can cause the symptoms of BPH. Additional screening tools include the use of the American Urological Association Symptom Index (AUA-SI) or the International Prostate Symptom Score (IPSS). The IPSS is an eight question written screening tool with seven symptom questions (scored 1 to 5) and one quality-of-life question (scored 1 to 6). The total score from the seven symptom questions is categorized as follows:

- 1-7: Mild BPH
- 8-19: Moderate BPH
- 20-35: Severe BPH

Treatment options that offer at least a three point improvement in IPSS are considered clinically meaningful by urologists. The IPSS is the primary clinical endpoint that has been utilized for the approval of products that are used for treating the symptoms of BPH.

PRX302 for Treating BPH

PRX302 is administered to patients through an ultrasound-guided series of injections into the prostate that takes approximately four minutes to complete. The procedure can be completed during a short office visit and is currently being developed as a one-time use procedure. PRX302 is designed to be safe, simple, convenient, and provide rapid, sustained relief of BPH symptoms. It has been tested thus far in five clinical trials involving 365 BPH patients.

Plus-1 Study (PRX302-3-01): This was a Phase 3 randomized, double blind, placebo controlled study of a transperineal intraprostatic injection of 0.6 µg PRX302/g of prostate. The trial enrolled 239 men to be treated with PRX302 and 240 men to be treated with placebo. The primary endpoint of the trial was the change from baseline in IPSS at 52 weeks with secondary endpoints examining change in Qmax (maximum urine flow) at 6, 12, 18, 26, 32, 39, and 52 weeks along with the change in IPSS at each of those same time points.

Results from the Phase 3 study showed that injection of PRX302 resulted in a statistically significant improvement in IPSS total score from baseline over 52 weeks (7.60 vs. 6.58; *P*=0.043). A secondary analysis of IPSS total score showed a maximal effect at week 18 between PRX302-treated and placebo-treated patients (8.31 vs. 6.89; *P*=0.012). The change from baseline in Qmax over 52 weeks showed a statistical trend with overall improvement of 1.77 mL/sec (*P*=0.055). In the quality of life portion of the IPSS questionnaire, treatment with PRX302 resulted in a statistically significant change from baseline for every post-baseline visit beginning at week 18 (reaching *P*=0.004). As shown in the following figure, the average change from baseline of -7.6 points puts PRX302 in between oral therapies and surgical procedures in terms of efficacy.



***Source*: Sophiris Bio, Inc.**

Just as with the Phase 2b study, adverse events were typically mild or moderate, occurred on the day of the injection, and were transient with a median duration of less than a day. There were also no indications of any adverse sexual or cardiovascular side effects.

Development Plan for PRX302 in BPH

Sophiris is currently evaluating options to advance PRX302 further in development for the treatment of BPH. A second Phase 3 clinical trial will be required in order to apply for approval with the FDA, which will cost a significant amount of money (we estimate approximately $35 million). While the company is currently uncertain about how exactly the second Phase 3 trial will be funded, it is likely that a non-dilutive partnership or royalty agreement will be utilized and that a second Phase 3 trial would not be initiated until such arrangement was procured.

Financial Update

On November 9, 2016, Sophiris (SPHS) announced financial results for the third quarter of 2016 and provided a business update. As expected, the company did not report any revenues. Sophiris reported a net loss of $4.3 million, or $0.17 per share. Research and development expenses totaled $0.6 million, compared with $2.6 million for the corresponding time period in 2015. This decrease was primarily due to a decrease in costs associated with the Phase 3 PLUS-1 clinical trial and the Phase 2a proof-of-concept trial for localized prostate cancer. General and administrative expenses totaled $3.0 million, compared to $0.9 million for the third quarter of 2015. This increase was primarily due to the inclusion of $1.4 million in offering expenses along with an increase in personnel related costs and professional services.

Sophiris exited the third quarter of 2016 with $31.3 million in cash and cash equivalents, due in part to public offering in August 2016 that raised net proceeds of $27.4 million. In addition, the company received proceeds of $1.7 million during the third quarter of 2016 from the exercise of warrants and stock options. In September 2016, the company repaid the outstanding principal balance of the loan with Oxford Finance LLC through a $4.2 million payment. As a result, the company currently has no long-term debt on the balance sheet.

Valuation

We value Sophiris using a probability adjusted discounted cash flow that takes into account potential future revenues from the sale of PRX302 in both BPH and prostate cancer. For both BPH and prostate cancer, we anticipate the company ultimately entering into collaboration before commercialization of PRX302. For modeling purposes, we are estimating a second Phase 3 study starting in BPH in 2018 and approval in 2021. For prostate cancer, we estimate the upcoming Phase 2b trial concluding by the end of 2017, a Phase 3 program completing by 2020 and approval in 2021.

Prostate cancer likely represents the greatest value proposition for the company, as PRX302 is highly differentiated from other therapies currently available and under development and the company generated very promising data from the proof-of-concept study that included two complete responses. We estimate approximately 180,000 men will develop prostate cancer in 2016 and that approximately 80% of those will have localized disease, 50% of which will require treatment for a total target population of approximately 72,000. We believe that PRX302 could attain 20% market share and have peak revenues of approximately $950 million in the U.S. and $850 million in the E.U. Using a 15% royalty rate, a 13% discount rate, and a 40% chance of approval, we estimate the net present value for PRX302 in prostate cancer to be $178 million.

For BPH, we model for a low market share for the approximately 4 million men who receive treatment for BPH and peak revenues of approximately $300 million. Using a 15% royalty rate, a 13% discount rate, and a 60% chance of approval, we estimate the net present value for PRX302 in BPH to be $46 million.

Combining the values for PRX302 in prostate cancer and BPH along with the company's current cash total and expected additional capital requirement of $30 million, we arrive at a net present value for the company of $225 million. Dividing this number by the fully diluted share count of approximately 37 million shares leads to a valuation of $6, and we note considerable upside is possible to this valuation with continued clinical success of PRX302 in the company's upcoming Phase 2b trial in prostate cancer.

PROJECTED FINANCIALS

Sophiris Bio, Inc.
Income Statement

Sophiris Bio, Inc.	2015 A	Q1 A	Q2 A	Q3 A	Q4 E	2016 E	2017 E	2018 E
PRX302 BPH	$0	$0	$0	$0	$0	$0	$0	$0
YOY Growth	-	-	-	-	-	-	-	
PRX302 Prostate Cancer	$0	$0	$0	$0	$0	$0	$0	$0
YOY Growth	-	-	-	-	-	-	-	
Grants & Collaborative Revenue	$0	$0	$0	$0	$0	$0	$0	$0
YOY Growth	-	-	-	-	-	-	-	
Total Revenues	**$0**	**$0**	**$0**	**$0**	**$0**	**$0**	**$0**	**$0**
YOY Growth	-	-	-	-	-	-	-	
Cost of Sales	$0	$0	$0	$0	$0	$0	$0	$0
Product Gross Margin	-	-	-	-	-	-	-	
Research & Development	$9.9	$0.9	$1.0	$0.6	$1.0	$3.5	$5.0	$8.0
General & Administrative	$3.6	$1.2	$1.4	$3.0	$1.2	$6.8	$5.5	$6.0
Other Expenses	$0	$0	$0	$0	$0	$0	$0	$0
Operating Income	($13.5)	($2.1)	($2.3)	($3.7)	($2.2)	($10.3)	($10.5)	($14.0)
Operating Margin	-	-	-	-	-	-	-	
Non-Operating Expenses (Net)	($0.7)	($0.1)	($1.8)	($0.6)	($0.1)	($2.6)	($0.5)	($0.5)
Pre-Tax Income	($14.2)	($2.2)	($4.1)	($4.3)	($2.3)	($12.9)	($11.0)	($14.5)
Income Taxes Paid	$0	$0	$0	$0	$0	$0	$0	$0
Tax Rate	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*
Net Income	**($14.2)**	**($2.2)**	**($4.1)**	**($4.3)**	**($2.3)**	**($12.9)**	**($11.0)**	**($14.5)**
Net Margin	-	-	-	-	-	-	-	
Reported EPS	**($0.84)**	**($0.13)**	**($0.21)**	**($0.17)**	**($0.08)**	**($0.56)**	**($0.33)**	**($0.41)**
YOY Growth	-	-	-	-	-	-	-	
Basic Shares Outstanding	16.9	17.2	19.3	25.2	30.0	22.9	33.0	35.0

Source: Zacks Investment Research, Inc. *David Bautz, PhD*

© Copyright 2016, Zacks Investment Research. All Rights Reserved.

HISTORICAL STOCK PRICE



© Copyright 2016, Zacks Investment Research. All Rights Reserved.

DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, David Bautz, PhD, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.
Zacks SCR has received compensation from the issuer directly or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business.
SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.